Data di Pubblicazione:
2021
Abstract:
Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure or death from cardiovascular causes among patients with stable heart failure. However, the safety and efficacy of SGLT2 inhibitors when initiated soon after an episode of decompensated heart failure are unknown.
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
Bhatt, Deepak L; Szarek, Michael; Steg, P Gabriel; Cannon, Christopher P; Leiter, Lawrence A; Mcguire, Darren K; Lewis, Julia B; Riddle, Matthew C; Voors, Adriaan A; Metra, Marco; Lund, Lars H; Komajda, Michel; Testani, Jeffrey M; Wilcox, Christopher S; Ponikowski, Piotr; Lopes, Renato D; Verma, Subodh; Lapuerta, Pablo; Pitt, Bertram
Link alla scheda completa:
Pubblicato in: